Newborn treatment with nevirapine plus zidovudine reduces mother-to-child transmission of HIV - 24/08/11
Abstract |
Question |
Is newborn treatment with nevirapine plus zidovudine safer and more effective than nevirapine alone in reducing mother-to-child HIV transmission?
Study design |
Twelve month follow-up of open randomised controlled trial.
Main results |
At 6–8 weeks, mother-to-child transmission of HIV was significantly lower with nevirapine plus zidovudine compared with nevirapine alone (15% vs. 21%, p=0.03). In babies HIV-negative at birth, HIV infection rates were significantly lower with nevirapine plus zidovudine compared with nevirapine alone at 6–8 weeks (8% vs. 12%, p=0.03). Adverse events were similar between groups (8% nevirapine plus zidovudine vs. 6% nevirapine alone, p=0.16).
Authors’ conclusions |
Babies of HIV-positive women who present too late for preterm counselling or treatment can be protected from HIV transmission. The addition of zidovudine to treatment with nevirapine reduces HIV transmission rate without increasing side-effects.
Le texte complet de cet article est disponible en PDF.Keywords : HIV infections, Mother-to-child transmission, Zidovudine, Nevirapine, Randomised controlled trial
Plan
 | Abstracted from: Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362: 1171–177. |
Vol 8 - N° 2
P. 85-86 - avril 2004 Retour au numéro
Article précédent
- Combined serum and nuchal translucency screening in the first trimester achieves 85% to 90% detection rate for Down and Edward syndromes
- Maj Hultén
- Nevirapine sustains reduction of mother-to-child HIV transmission at 18 months
- Thérèse Delvaux
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?